Pfizer (PFE) DIvidends Date & History

Key Takeaways

• Pfizer Inc. (PFE) offers a forward dividend yield of approximately 6.88%, significantly above the broader market average.
• The company pays a quarterly dividend of $0.43 per share, totaling $1.72 annually.
• Pfizer has raised its dividend for 17 consecutive years, supporting its status as a dividend growth stock.
• The payout ratio exceeds 130%, indicating potential pressure on sustainability amid recent earnings challenges.
• Free cash flow and earnings coverage warrant monitoring, though the firm maintains a long track record of payments.
• Relative to pharmaceutical peers, the yield stands out as elevated, appealing to income-focused investors.

Dividend Overview

Pfizer Inc. (PFE) maintains a consistent dividend policy with quarterly payments. The current annualized dividend totals $1.72 per share, delivering a yield near 6.88% based on recent share prices. This positions PFE as a high-yield dividend stock within the healthcare sector. The company has paid dividends for decades, including 349 consecutive quarterly distributions, and qualifies as a dividend growth stock due to its history of annual increases. Payments occur four times per year, with the most recent ex-dividend date on July 24, 2026, and the payable date set for September 1, 2026.

Dividend History and Growth

Pfizer has demonstrated steady dividend growth over time, with an average annual increase of about 2.4% over the past three years and roughly 2.37% over five years. The firm has raised its dividend for 17 straight years, reflecting a commitment to returning capital to shareholders. Recent adjustments have been modest but consistent, with the quarterly rate holding at $0.43 after prior increments. This long-term strategy emphasizes reliability rather than aggressive hikes, aligning with the company’s mature pharmaceutical business model.

Dividend Sustainability and Payout Ratio

The dividend payout ratio currently exceeds 130%, meaning distributions outpace reported earnings. This level raises questions about long-term sustainability, particularly given recent earnings pressures from product transitions and impairments. Free cash flow coverage provides some buffer, yet elevated debt and variable profitability require ongoing attention. Despite the high ratio, Pfizer’s strong balance sheet and diversified portfolio support continued payments. Investors should watch upcoming earnings reports for signs of improved coverage.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, PFE’s yield of approximately 6.88% exceeds that of peers such as Bristol-Myers Squibb (BMY) at around 3.84%. Other large-cap healthcare names typically offer lower yields in the 2-4% range. This premium reflects market pricing of recent challenges but also highlights PFE’s appeal for income generation compared with industry averages.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover similar opportunities.

Is This Stock Attractive for Dividend Investors?

PFE may suit income-oriented investors seeking above-average yields in the healthcare space. Its established dividend growth history appeals to those prioritizing consistency over rapid increases. Conservative long-term holders could value the quarterly payment schedule and multi-decade track record, though the elevated payout ratio suggests monitoring earnings closely. Dividend growth investors may find the modest recent increases acceptable given the overall yield. The stock appears less ideal for those focused solely on rapid dividend expansion or ultra-conservative payout ratios below 60%. Overall, it offers a balanced profile for investors comfortable with sector-specific risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations